MedTrace Logo

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

NCT05077800 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-04-13

No results posted yet for this study

Summary

The purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant to standard treatment for the disease.

The names of the study drugs involved in this study are:

* 9-ING-41
* Losartan
* Ferumoxytol
* FOLFIRINOX (made up of 4 different drugs):

* 5-Fluorouracil (5-FU)
* Oxaliplatin
* Irinotecan
* Leucovorin

Conditions

  • Pancreatic Adenocarcinoma
  • Pancreatic Adenocarcinoma Metastatic

Interventions

DRUG

FOLFIRNINOX

Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion

DRUG

Losartan

Taken Orally

DRUG

9-ING-41

Administered by intravenous infusion

Sponsors & Collaborators

  • Actuate Therapeutics Inc.

    collaborator INDUSTRY

  • Lustgarten Foundation

    collaborator OTHER

  • Colin D. Weekes, M.D., PhD

    lead OTHER

Principal Investigators

  • Colin D Weekes, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-21
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05077800 on ClinicalTrials.gov